NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

10229	Companies
211139	Keywords
141059	Articles
111848	Press releases

Home
Companies
NANOBIOTIX

BRIEF

published on 05/28/2024 at 22:20, 1 year 10 months ago

NANOBIOTIX Presents New Data at ASCO 2024

Immunotherapy NANOBIOTIX NBTXR3 ASCO Phase 1
PRESS RELEASE

published on 05/28/2024 at 22:15, 1 year 10 months ago

NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
Nanobiotix to present new data from Phase 1 immunotherapy program at 2024 ASCO meeting followed by investor conference call. Details for the call provided

Investor Conference Call Immunotherapy ASCO 2024 NANOBIOTIX Phase 1
BRIEF

published on 05/23/2024 at 22:20, 1 year 10 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference

Biotechnology Cancer Treatment Webcast NANOBIOTIX Jefferies Global Healthcare Conference
PRESS RELEASE

published on 05/23/2024 at 22:15, 1 year 10 months ago

NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
Nanobiotix to present at the Jefferies Global Healthcare Conference on June 5, 2024, with Bart Van Rhijn, CFO, participating in a fireside chat. Company pioneering physics-based approaches for cancer treatment

Cancer Treatment Biotechnology Company NANOBIOTIX Jefferies Global Healthcare Conference Physics-based Approaches
BRIEF

published on 05/21/2024 at 22:20, 1 year 10 months ago

Nanobiotix Announces Advancement in NBTXR3 Development and Strategic Collaboration

Biotechnology Cancer Therapy NANOBIOTIX NBTXR3 Janssen Collaboration
PRESS RELEASE

published on 05/21/2024 at 22:15, 1 year 10 months ago

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix announces progress in global NBTXR3 development collaboration, highlighting robust pipeline and pathway to long-term growth in cancer treatment. Updates include US FDA approvals and strategic study modifications

Cancer Treatment NANOBIOTIX NBTXR3 Global Development FDA Approvals
BRIEF

published on 05/14/2024 at 22:20, 1 year 11 months ago

NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval

FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
PRESS RELEASE

published on 05/14/2024 at 22:15, 1 year 11 months ago

NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients

Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol

Accesswire

Published on 04/16/2026 at 15:55, 5 hours 21 minutes ago

TripSitter Announces Director Resignation
Published on 04/16/2026 at 15:20, 5 hours 56 minutes ago

Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 2026
Published on 04/16/2026 at 15:00, 6 hours 16 minutes ago

FaZe Esports, a GameSquare Company, Announces Partnership with CORSAIR
Published on 04/16/2026 at 14:44, 6 hours 32 minutes ago

Worksport to Showcase SOLIS(TM), COR(TM) and Expanded Product Line at the 2026 MOORE Overlanding Expo
Published on 04/16/2026 at 14:35, 6 hours 41 minutes ago

LQR House Inc. Announces Agreement to Acquire 100% of Fusion Five Continents Limited, a Next-Generation Cross-Border Securities and Digital Asset Trading Platform

View all ACCESSWIRE

EQS Group

Published on 04/16/2026 at 21:00, 15 minutes ago

Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 40 minutes ago

EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 1 hour 58 minutes ago

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 18:57, 2 hours 19 minutes ago

Op-Ed: Africa’s Energy Wealth: Why Good Governance Must Power a Just Transition (By Sola Adebawo)
Published on 04/16/2026 at 18:06, 3 hours 10 minutes ago

SIG Group AG holds 2026 Annual General Meeting

Les Echos

Published on 04/16/2026 at 18:02, 3 hours 14 minutes ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 18:00, 3 hours 16 minutes ago

ICADE – PR – Q1 2026 TRADING UPDATE
Published on 04/16/2026 at 17:55, 3 hours 20 minutes ago

Publication of 2026 1st quarter turnover
Published on 04/16/2026 at 17:54, 3 hours 21 minutes ago

Aéroports de Paris S.A - March 2026 traffic figures
Published on 04/16/2026 at 17:45, 3 hours 31 minutes ago

VOGO : 2025 full-year results.

View all LES ECHOS COMFI WIRE